Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GT 00A x IL15

Next Previous
Search
Drug Profile

GT 00A x IL15

Alternative Names: Anti TA-MUC1 antibody cytokine conjugate - Glycotope; GT 00A based IL 15 immuno-cytokine - Glycotope; GT-00A based IL-15 immuno-cytokine; GT-00A x IL15; TA-MUC1 x IL-15; TA-MUC1 x IL15 - Glycotope; TA-MUC1-targeting IL-15 fusion antibody - Glycotope

Latest Information Update: 12 Oct 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glycotope
  • Class Antibodies; Antineoplastics; Cytokines; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Interleukin 15 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 12 Oct 2023 GT 00A x IL15 is still in preclinical phase for Cancer in Germany (Glycotope Pipeline, October 2023)
  • 13 Dec 2022 Therabest Korea and Glycotope enters into an agreement for the clinical development of GT 00A x IL15 in Triple-negative breast cancer (Combination therapy)
  • 13 Dec 2022 Therabest Korea and Glycotope plans clinical trials in Triple-negative breast cancer (Combination therapy)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top